Practices ordering gloves, instruments, and consumables this year have likely noticed something: the invoice total keeps climbing, even when the order looks identical to last quarter's. That's not a pricing error. It's the cumulative effect of tariff policy working its way through the dental and medical supply chain.
What's Driving the Increase
According to the Dental Trade Alliance's January 2026 white paper on regulatory and legislative policies reshaping dental utilization, Section 301 tariffs on dental and medical supplies increased 50% in 2025, with a 100% increase projected for 2026. That means the cost of gloves, instruments, impression materials, and other consumables is doubling relative to pre-tariff baselines.
Gloves have been especially affected. U.S. tariffs on medical-grade gloves from China are escalating dramatically, jumping from 7.5% to 50% on January 1, 2025, and reaching 100% by January 1, 2026. These increases, combined with tariffs on gloves from alternative manufacturing countries like Vietnam (46%), Thailand (36%), Indonesia (32%), and Malaysia (24%), mean that dental practices face substantial cost pressures across their entire supply chain—not just for gloves, but for patient towels, face masks, tray covers, surface wipes, and other essential protection and patient consumables.
The squeeze isn't limited to a single category. Across the board, dental supply costs rose 10-12% in 2025. Disposables, anesthetics, restorative materials, lab fees - all up. Inflation hit the dental supply chain hard, and distributors passed it straight to you. Raw material costs have compounded the issue: Nitrile gloves, resins, metals (for burs and instruments) - raw material costs spiked 8-15% due to supply chain disruptions and commodity price increases.
Why This Matters Beyond the Invoice
Rising input costs are colliding with reimbursement rates that haven't kept pace. This supply-side cost explosion is colliding directly with a revenue-side problem: insurance reimbursement rates are not keeping pace. The result is a widening margin gap that practice managers can't simply absorb quarter after quarter without a plan.
Sourcing pressure adds another layer of risk. Manufacturers are scrambling to shift production outside China, but plants in alternative countries are already at capacity. Some suppliers have cancelled orders entirely with no ability to re-source. For practices, that translates into both higher prices and less predictable availability for certain PPE and consumable lines.
How Practices Can Respond
- Audit your top supply lines. Identify the products most exposed to tariff-driven cost swings — gloves, masks, and imported instruments are common culprits — and model the budget impact before it shows up as a surprise.
- Diversify sourcing where clinically appropriate. Suppliers with multi-country sourcing options may be better positioned to absorb volatility than single-source vendors.
- Compare generic and equivalent products. Clinically equivalent alternatives in categories like gloves and consumables can offer meaningful savings without compromising quality.
- Watch federal shortage lists. The FDA's Medical Device Shortages List is updated periodically and can flag categories at elevated risk before a full-blown shortage hits your order.
- Lock in pricing where possible. Contract or price-lock agreements with distributors can provide short-term budget stability while trade policy remains in flux.
Tariff policy can shift with little notice, so practices should treat current pricing as a moving target rather than a fixed baseline. Building flexibility into procurement now — rather than reacting order by order — is the most reliable way to protect both margins and continuity of care.